Outlook Therapeutics is deeply undervalued after an FDA denial caused a 70-80% drop, with a likely correction and long-term entry opportunity.
OTLK — LONG The author claims ONS-5010 (LYTENAVA) is approved in Europe and UK for wet-AMD, a market estimated at $10-12B annually, and the recent FDA denial caused a 70-80% price drop that is a massive oversell. He expects a near-term correction and sees a great entry for long-term investors at current cheap prices. Primary risks stated are company financials, dilution risk, and poor cash runway.
This denial resulted in share price drop by 70 - 80 percent which is huge oversell in my modest opinion and correction is almost certain.
This Reddit post, published January 05, 2026, features u/LazyBondar discussing OTLK. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/LazyBondar · Tickers: OTLK